1. OS is very encouraging, wasn't expecting to see that data unfolding yet.
2. Toxicity was surprisingly low.
Both of these bode well for ongoing development in HCC and as combination therapy with immune therapies.
I think Exel can stick around now with careful partnering deals and build out their franchise.
Interested to see PD1 and Cabo in NSCLC and urothelial.
Also, with Cobi coming the end of 2015 looks very promising.
BMY obviously strategically timed their news, but more options for patients is good; patients are the winners today.
Are you saying all the "events" have occurred? I thought they were still awaiting events because of slowing in frequency of people coming off trial. No?
No two ways about it, very strong data, very positive meeting for Exel. Wondering how that affects share price over a few day period of time is foolish IMO. That is not the point. What it means as I see it: a very active, reasonably well-tolerated compound, that continues to show itself as a member of the future armamentarium against multiple different cancers. It likely will be used alone and in various combinations for years to come.
Exel, IMO, does not have the brains nor the financial wherewithal to bring to fruition all of those potentialities, and a buyer, or strong partner is in the wings. Roche is the natural choice, though there may be others wanting to compete against Roche.
What each positive trial means is the value of Cabo and Cobi increases the value of that partnership or that buyout someday.
I am happy to be sitting long.
I would think that there are numerous short agencies contemplating their next move today, and not feeling that warm fuzzy feeling that many longs are likely enjoying right now.
I enjoy the science, I enjoy the struggle against cancer, and the more weapons those scientists give me the better I feel getting up tomorrow morning and telling my patients...that hope springs eternal.
If this is such an obvious crime that hurts Exel, why doesn't Exel attorney counsel file an official complaint, launch an investigation?
I give lots of TKIs...and grade 1-2 toxicities are common. Zytiga has grade 1-2 fatigue (sometimes 3-4) frequently...I am not in the least bit surprised when you ADD two TKis together you get ADDitive toxicities (and hopefully in exchange for that you get synergistic efficacy). Anyone who would expect otherwise is a fool. As I see it these sort of toxicity assessments ahve no relation to either Meteor or the interesting data on single-agent Cabo in EGFR-WT NSCLC (a potential blockbuster indication).
I am staying long and strong myself, and ignoring the noise.
Not adding shares mind you, but holding.
...which is a great unasked for bonus coming out of this ASCO...a potential additional indication in the future and/or leverage in buyout negotiations.
As a practicing Medical Oncologist I can tell you that if this trial shows stat sig benefit compared to afinitor of course it will be used preferentially. Why wouldn't we? What you are proposing is that we shrug off data and go about our daily business like mindless mules.